Relapsed Refractory Multiple MyelomaPhase 3DURGA-4NCT07391657

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

A Phase 3 study testing AZD0120, Daratumumab and Carfilzomib in people with Relapsed Refractory Multiple Myeloma, run by AstraZeneca at 143 sites in 15 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts

Official record

Search all trials

Trial summary

This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of AZD0120 versus standard regimens (DKd [daratumumab, carfilzomib, and dexamethasone], DPd [daratumumab, pomalidomide, and dexamethasone], PVd [pomalidomide, bortezomib and dexamethasone], or Kd… Read more about this study

Who is it for?: Ages 18 years and older
Conditions the study is for: Relapsed Refractory Multiple Myeloma
What is being tested?: AZD0120, Daratumumab and Carfilzomib
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 508 participants
Where: 143 sitesin 15 countries
Study dates: 23 Feb 2026to 29 Jul 2030
Phase: Phase 3
Are there results?: Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 years and older
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

Age ≥ 18 years
Documented diagnosis of multiple myeloma according to the IMWG diagnostic criteria
Documented evidence of measurable disease:
Serum M-protein level ≥ 1 g/dL
Urine M-protein level ≥ 200 mg/24h
Serum immunoglobulin free light chain ≥ 10 mg/dL (100 mg/L) and abnormal serum immunoglobulin kappa lambda free light chain ratio

Show all 16Show fewer

Documented evidence of PD by IMWG 2016 criteria based on investigator's determination during or after the most recent line of therapy. Participants with only 1 prior line of therapy must have progressed within 47 months of a stem cell transplant, or if not transplanted, then within 42 months of starting initial therapy
Received 1 to 3 lines of prior therapy including an IMiD and either a PI or a CD38 antibody. Participant must have undergone at least 2 complete cycles of treatment for each line of therapy, unless PD was the best response to the line of therapy
Eligible to receive at least one of the standard regimens (DKd, PVd, DPd, or Kd) as determined by the Investigator.
ECOG performance status score of 0 to 1
Adequate hematology and chemistry laboratory values:
Haemoglobin ≥ 8.0 g/dL
Absolute neutrophil count ≥ 1 × 10^9/L (1000 per mm3)
Platelet count ≥ 75 × 10^9/L (75000 per mm3) in participants with < 50% of bone marrow nucleated cells are plasma cells or ≥ 50 × 10^9/L (50000 per mm3) in participants with ≥ 50% of bone marrow nucleated cells are plasma cells
Absolute lymphocyte count ≥ 300/µL (0.3 × 109/L)
Total bilirubin ≤ 1.5 × ULN in the absence of Gilbert's syndrome or ≤ 3 × ULN if the participant has Gilbert's syndrome. AST and ALT≤ 3.0 × ULN. CrCl by Cockcroft and Gault method ≥ 30 mL/minute

Who cannot join

Known active, or prior history of CNS involvement or exhibits clinical signs of meningeal involvement of MM.
Primary amyloidosis, active plasma cell leukaemia, Waldenstrom macroglobulinemia or Polyneuropathy Organomegaly Endocrinopathy M-protein and Skin (POEMS) syndrome.
Participants with primary refractory MM (failed to generate at least a minimal response to any prior therapy)
Significant neurological or psychiatric condition
Significant medical condition that places the participant at an unacceptable risk for treatment-related complications
Previously received any prior BCMA-targeted treatment

Show all 9Show fewer

Previously received CAR-T or CAR-NK therapy directed at any target
Previously received T-cell engager therapy directed at any target
Previously received allogeneic stem cell transplantation at any time during prior therapy or received autologous stem cell transplantation within 12 weeks of randomization

Trial locations and contacts

143 sites in 15 countries. Contact the study team or a site near you to ask about taking part.

AstraZeneca Clinical Study Information Center contact

1-877-240-9479

information.center@astrazeneca.com

Country

City, postcode or hospital

Sites recruiting now only

143 sites in 15 countries

United States51 sites, 36 recruiting

Research Site
Albany, New York, 12208
Not yet recruiting
Research Site
Atlanta, Georgia, 30322
Recruiting
Research Site
Austin, Texas, 78704
Recruiting
Research Site
Boston, Massachusetts, 02114
Not yet recruiting
Research Site
Boston, Massachusetts, 02215
Not yet recruiting
Research Site
Boston, Massachusetts, 02215
Withdrawn
Research Site
Chapel Hill, North Carolina, 27514
Not yet recruiting
Research Site
Charleston, South Carolina, 29425
Withdrawn
Research Site
Charlotte, North Carolina, 28204
Not yet recruiting
Research Site
Charlotte, North Carolina, 28204
Recruiting
Research Site
Charlottesville, Virginia, 22908
Withdrawn
Research Site
Chicago, Illinois, 60612
Not yet recruiting
Research Site
Cincinnati, Ohio, 45220
Not yet recruiting
Research Site
Cleveland, Ohio, 44195
Not yet recruiting
Research Site
Coral Gables, Florida, 33156
Withdrawn
Research Site
Dallas, Texas, 75235
Not yet recruiting
Research Site
Denver, Colorado, 80218
Recruiting
Research Site
Detroit, Michigan, 48201
Withdrawn
Research Site
Detroit, Michigan, 48202
Withdrawn
Research Site
Gainesville, Virginia, 20155
Not yet recruiting
Research Site
Gilbert, Arizona, 85234
Not yet recruiting
Research Site
Houston, Texas, 77030
Recruiting
Research Site
Iowa City, Iowa, 52242
Withdrawn
Research Site
Kansas City, Kansas, 66160
Not yet recruiting
Research Site
La Jolla, California, 92093
Withdrawn
Research Site
Louisville, Kentucky, 40207
Recruiting
Research Site
Madison, Wisconsin, 53792
Not yet recruiting
Research Site
Milwaukee, Wisconsin, 53226
Recruiting
Research Site
Nashville, Tennessee, 37203
Recruiting
Research Site
New Haven, Connecticut, 06510
Recruiting
Research Site
New York, New York, 10016
Withdrawn
Research Site
New York, New York, 10029
Recruiting
Research Site
New York, New York, 10065
Withdrawn
Research Site
New York, New York, 10065
Recruiting
Research Site
Park Ridge, Illinois, 60068
Not yet recruiting
Research Site
Phoenix, Arizona, 85054
Withdrawn
Research Site
Portland, Oregon, 97239
Not yet recruiting
Research Site
Puyallup, Washington, 98373
Not yet recruiting
Research Site
Richmond, Virginia, 23298
Withdrawn
Research Site
Rochester, Minnesota, 55905
Withdrawn
Research Site
Rochester, New York, 14642
Withdrawn
Research Site
Sacramento, California, 95817
Not yet recruiting
Research Site
Salt Lake City, Utah, 84112
Not yet recruiting
Research Site
Santa Monica, California, 90404
Not yet recruiting
Research Site
Seattle, Washington, 98104
Recruiting
Research Site
Tampa, Florida, 33606
Not yet recruiting
Research Site
The Bronx, New York, 10467
Withdrawn
Research Site
Tucson, Arizona, 85719
Not yet recruiting
Research Site
Washington D.C., District of Columbia, 20007
Not yet recruiting
Research Site
Winston-Salem, North Carolina, 27103
Recruiting
Research Site
Winston-Salem, North Carolina, 27157
Not yet recruiting

Other trials in United States

China24 sites, 24 recruiting

Research Site
Beijing, 100024
Not yet recruiting
Research Site
Beijing, 100044
Not yet recruiting
Research Site
Changchun, 130021
Not yet recruiting
Research Site
Changsha, 410008
Not yet recruiting
Research Site
Changsha, 410013
Not yet recruiting
Research Site
Chongqing, 400030
Not yet recruiting
Research Site
Guangzhou, 510000
Not yet recruiting
Research Site
Guangzhou, 510700
Not yet recruiting
Research Site
Hefei, 230601
Not yet recruiting
Research Site
Nanchang, 330000
Not yet recruiting
Research Site
Nanchang, 330006
Not yet recruiting
Research Site
Nanjing, 210000
Not yet recruiting
Research Site
Ningbo, 315040
Not yet recruiting
Research Site
Shanghai, 200025
Not yet recruiting
Research Site
Shanghai, 200065
Not yet recruiting
Research Site
Shanghai, 201210
Not yet recruiting
Research Site
Shenzhen, 518039
Not yet recruiting
Research Site
Tianjin, 300020
Not yet recruiting
Research Site
Wenzhou, 325000
Not yet recruiting
Research Site
Wuhan, 430030
Not yet recruiting
Research Site
Xi'an, 710004
Not yet recruiting
Research Site
Xi'an, 710061
Not yet recruiting
Research Site
Zhengzhou, 450000
Not yet recruiting
Research Site
Zhengzhou, 450008
Not yet recruiting

Other trials in China

Germany11 sites, 11 recruiting

Research Site
Berlin, 12200
Not yet recruiting
Research Site
Dresden, 01307
Not yet recruiting
Research Site
Erlangen, 91054
Not yet recruiting
Research Site
Essen, 45147
Not yet recruiting
Research Site
Freiburg im Breisgau, 79106
Not yet recruiting
Research Site
Hamburg, 20246
Recruiting
Research Site
Leipzig, 04103
Not yet recruiting
Research Site
Mainz, 55131
Not yet recruiting
Research Site
München, 81675
Not yet recruiting
Research Site
Nuremberg, 90419
Not yet recruiting
Research Site
Würzburg, 97080
Not yet recruiting

Other trials in Germany

Australia7 sites, 7 recruiting

Research Site
Camperdown, 2050
Recruiting
Research Site
Darlinghurst, 2010
Recruiting
Research Site
Fitzroy, VIC3065
Recruiting
Research Site
Liverpool, 2170
Not yet recruiting
Research Site
Melbourne, 3000
Recruiting
Research Site
Melbourne, 3004
Recruiting
Research Site
Murdoch, WA6150
Not yet recruiting

Other trials in Australia

Spain7 sites, 7 recruiting

Research Site
Barcelona, 08036
Not yet recruiting
Research Site
Barcelona, 8035
Not yet recruiting
Research Site
Madrid, 28041
Recruiting
Research Site
Pamplona, 31008
Not yet recruiting
Research Site
Salamanca, 37007
Not yet recruiting
Research Site
Santander, 39008
Recruiting
Research Site
Valencia, 46026
Not yet recruiting

Other trials in Spain

France6 sites, 6 recruiting

Research Site
Lille, 59037
Not yet recruiting
Research Site
Nantes, 44093
Not yet recruiting
Research Site
Paris, 75010
Not yet recruiting
Research Site
Pierre-Bénite, 69495
Not yet recruiting
Research Site
Poitiers, 86021
Not yet recruiting
Research Site
Toulouse, 31059
Not yet recruiting

Other trials in France

Italy6 sites, 6 recruiting

Research Site
Bologna, 40138
Not yet recruiting
Research Site
Milan, 20132
Not yet recruiting
Research Site
Milan, 20133
Not yet recruiting
Research Site
Naples, 80131
Not yet recruiting
Research Site
Rozzano, 20089
Not yet recruiting
Research Site
Torino, 10126
Not yet recruiting

Other trials in Italy

Japan6 sites, 6 recruiting

Research Site
Bunkyō City, 113-8431
Recruiting
Research Site
Kashiwa, 277-8577
Recruiting
Research Site
Kyoto, 602-8566
Recruiting
Research Site
Nagoya, 467-8602
Recruiting
Research Site
Shibuya-ku, 150-8935
Recruiting
Research Site
Shinjuku-ku, 160-8582
Recruiting

Other trials in Japan

Poland6 sites, 6 recruiting

Research Site
Gdansk, 80-952
Not yet recruiting
Research Site
Gliwice, 44-101
Recruiting
Research Site
Lublin, 20-090
Not yet recruiting
Research Site
Poznan, 60-569
Not yet recruiting
Research Site
Warsaw, 02-776
Not yet recruiting
Research Site
Wroclaw, 50-367
Not yet recruiting

Other trials in Poland

Canada4 sites, 4 recruiting

Research Site
Calgary, Alberta, T2N 5G2
Not yet recruiting
Research Site
Montreal, Quebec, H3A 1A1
Recruiting
Research Site
Toronto, Ontario, M5G 2M9
Recruiting
Research Site
Vancouver, British Columbia, V5Z 4E6
Not yet recruiting

Other trials in Canada

South Korea4 sites, 4 recruiting

Research Site
Seoul, 03080
Not yet recruiting
Research Site
Seoul, 06351
Not yet recruiting
Research Site
Seoul, 06591
Not yet recruiting
Research Site
Seoul, 5505
Not yet recruiting

Other trials in South Korea

United Kingdom4 sites, 4 recruiting

Research Site
Birmingham, B9 5SS
Recruiting
Research Site
Bristol, BS2 8ED
Recruiting
Research Site
Glasgow, Scotland, G12 0YN
Not yet recruiting
Research Site
London, SM2 5NG
Recruiting

Other trials in United Kingdom

Brazil3 sites, 3 recruiting

Research Site
Salvador, 41253-190
Recruiting
Research Site
São Paulo, 01509-900
Recruiting
Research Site
São Paulo, 05652-900
Recruiting

Other trials in Brazil

Taiwan3 sites, 3 recruiting

Research Site
Taipei, 10002
Recruiting
Research Site
Taipei, 106
Recruiting
Research Site
Taipei, 112
Recruiting

Other trials in Taiwan

Norway1 site, 1 recruiting

Research Site
Oslo, 0450
Recruiting

Other trials in Norway

About this study

Official title: A Phase III Open-label, Randomised, Multicentre Study Comparing AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CART) Therapy Directed Against BCMA and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma.

Conditions: Relapsed Refractory Multiple Myeloma
Being tested: AZD0120, Daratumumab, Carfilzomib, Dexamethasone, Bortezomib
Keywords: BCMA, CAR-T, CD19
Medical subject headings: Multiple Myeloma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

AZD0120Biological
CAR-T Cells
DaratumumabDrug
Also called Darzalex
Daratumumab
CarfilzomibDrug
Also called Kyprolis
Carfilzomib
DexamethasoneDrug
Dexamethasone
BortezomibDrug
Also called Velcade
Bortezomib
PomalidomideDrug
Also called Pomalyst and Imnovid
Pomalidomides

Study groups in NCT07391657
Study group	Role	What they receive
Arm A	Experimental	AZD0120 Receives: Biological: AZD0120
Arm B	Active comparator	1 of the following 4 standard regimens per investigator choice; DKd, DPd, PVd, Kd. Receives: Drug: Daratumumab; Drug: Carfilzomib; Drug: Dexamethasone; Drug: Bortezomib; Drug: Pomalidomide

What is being measured

The primary outcome is the main question the study is designed to answer.

To demonstrate the superiority of AZD0120 relative to standard therapy (DKd, DPd, PVd, or Kd) by assessment of PFS in participants with RRMM.
PFS: defined as time from randomisation until progression according to IMWG 2016 criteria as assessed by BICR, or death due to any cause, whichever occurs first.
Measured: 3 years
To demonstrate the superiority of AZD0120 relative to standard therapy (DKd, DPd, PVd, or Kd) by assessment of MRD negativity rate at 9 months in participants with RRMM.
MRD negative CR rate at 9 months: defined as the proportion of participants with MRD negative status and have a response of CR or sCR (according to the IMWG 2016 criteria) at 9 months (± 3 months) from randomisation before initiation of subsequent anti-myeloma therapy.
Measured: 2 years

Secondary outcomes (3)

To further demonstrate the effectiveness of AZD0120 relative to standard therapy (DKd, DPd, PVd, or Kd) by assessment of CRR in participants with RRMM.
Measured: 2 years
To further demonstrate the effectiveness of AZD0120 relative to standard therapy (DKd, DPd, PVd, or Kd) by assessment of ORR in participants with RRMM.
Measured: 2 years
To further demonstrate the effectiveness of AZD0120 relative to standard therapy (DKd, DPd, PVd, or Kd) by assessment of OS in participants with RRMM.
Measured: 5 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

23 Feb 202629 Jul 2030

First posted6 Feb 2026
Study start23 Feb 2026
Primary completion14 Jun 2028 (estimated)
Study completion29 Jul 2030 (estimated)

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Other trials for Relapsed Refractory Multiple MyelomaStudies of the same condition, open and under way.
More trials run by AstraZenecaThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 3
Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Model description: Open-label
Masking: None (open label)
Enrolment: 508 participants (estimated)

IDs, dates and publications

ClinicalTrials.gov ID: NCT07391657
Sponsor's protocol ID: D8311C00001
Other IDs: AZD0120
Acronym: DURGA-4
Status last verified: Sep 2026
First submitted: 30 Jan 2026
Last updated: 29 Sep 2026
Results posted: No
Data monitoring committee: Yes
FDA-regulated drug: Yes
FDA-regulated device: No
Individual data sharing: Yes: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Interested in taking part?

AstraZeneca Clinical Study Information Center

1-877-240-9479

information.center@astrazeneca.com

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See sites and contacts

RecruitingPhase 1/2
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
RecruitingPhase 1
Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma
Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed or Refractory Multiple Myeloma (MM)
RecruitingPhase 1/2
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
RecruitingPhase 2
18F-Fluciclovine PET/CT in Multiple Myeloma
Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM)
Active, not recruitingPhase 2
A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
Plasma Cell Myeloma Refractory

All Relapsed Refractory Multiple Myeloma trials

Study at a glance

From the registry record, last updated by the sponsor on 29 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: A Phase III Open-label, Randomised, Multicentre Study Comparing AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CART) Therapy Directed Against BCMA and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma.
ClinicalTrials.gov ID: NCT07391657
Acronym / sponsor ID: DURGA-4 / D8311C00001
Conditions: Relapsed Refractory Multiple Myeloma
Keywords: BCMA, CAR-T, CD19
Phase: Phase 3
Study type: Interventional
Recruitment status: Recruiting
Enrolment: 508 participants (estimated)
Lead sponsor: AstraZenecaIndustry (pharma, biotech, devices)
Study start: 23 Feb 2026 (actual)
Primary completion: 14 Jun 2028 (estimated)
Study completion: 29 Jul 2030 (estimated)
First posted: 6 Feb 2026 (actual)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Study design

Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: None (open label)
Number of arms: 2
Model description: Open-label

Arm	Type	Receives
Arm A	Experimental	Biological: AZD0120AZD0120
Arm B	Active comparator	Drug: Daratumumab, Drug: Carfilzomib, Drug: Dexamethasone, Drug: Bortezomib, Drug: Pomalidomide1 of the following 4 standard regimens per investigator choice; DKd, DPd, PVd, Kd.

Who may qualify

Ages: 18 years and older
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (16 listed)

Age ≥ 18 years
Documented diagnosis of multiple myeloma according to the IMWG diagnostic criteria
Documented evidence of measurable disease:
Documented evidence of PD by IMWG 2016 criteria based on investigator's determination during or after the most recent line of therapy. Participants with only 1 prior line of therapy must have progressed within 47 months of a stem cell transplant, or if not transplanted, then within 42 months of starting initial therapy
Received 1 to 3 lines of prior therapy including an IMiD and either a PI or a CD38 antibody. Participant must have undergone at least 2 complete cycles of treatment for each line of therapy, unless PD was the best response to the line of therapy

Key exclusion criteria (9 listed)

Known active, or prior history of CNS involvement or exhibits clinical signs of meningeal involvement of MM.
Primary amyloidosis, active plasma cell leukaemia, Waldenstrom macroglobulinemia or Polyneuropathy Organomegaly Endocrinopathy M-protein and Skin (POEMS) syndrome.
Participants with primary refractory MM (failed to generate at least a minimal response to any prior therapy)
Significant neurological or psychiatric condition
Significant medical condition that places the participant at an unacceptable risk for treatment-related complications

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
AZD0120CAR-T Cells	Biological	Arm A
DaratumumabAlso: DarzalexDaratumumab	Drug	Arm B
CarfilzomibAlso: KyprolisCarfilzomib	Drug	Arm B
DexamethasoneDexamethasone	Drug	Arm B
BortezomibAlso: VelcadeBortezomib	Drug	Arm B
PomalidomideAlso: Pomalyst and ImnovidPomalidomides	Drug	Arm B

Primary outcome

To demonstrate the superiority of AZD0120 relative to standard therapy (DKd, DPd, PVd, or Kd) by assessment of PFS in participants with RRMM.
Time frame: 3 years
PFS: defined as time from randomisation until progression according to IMWG 2016 criteria as assessed by BICR, or death due to any cause, whichever occurs first.
To demonstrate the superiority of AZD0120 relative to standard therapy (DKd, DPd, PVd, or Kd) by assessment of MRD negativity rate at 9 months in participants with RRMM.
Time frame: 2 years
MRD negative CR rate at 9 months: defined as the proportion of participants with MRD negative status and have a response of CR or sCR (according to the IMWG 2016 criteria) at 9 months (± 3 months) from randomisation before initiation of subsequent anti-myeloma therapy.

3 secondary outcomes

To further demonstrate the effectiveness of AZD0120 relative to standard therapy (DKd, DPd, PVd, or Kd) by assessment of CRR in participants with RRMM.
Time frame: 2 years
To further demonstrate the effectiveness of AZD0120 relative to standard therapy (DKd, DPd, PVd, or Kd) by assessment of ORR in participants with RRMM.
Time frame: 2 years
To further demonstrate the effectiveness of AZD0120 relative to standard therapy (DKd, DPd, PVd, or Kd) by assessment of OS in participants with RRMM.
Time frame: 5 years

Results and safety

This study is still under way. Results are not available in the source record yet.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 29 Sep 2026.
Individual participant dataSharing planned: Yes. Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Related trials for Relapsed Refractory Multiple Myeloma

RecruitingPhase 1/2
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
RecruitingPhase 1
Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma
Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed or Refractory Multiple Myeloma (MM)
RecruitingPhase 1/2
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
RecruitingPhase 2
18F-Fluciclovine PET/CT in Multiple Myeloma
Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM)
Active, not recruitingPhase 2
A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
Plasma Cell Myeloma Refractory

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.

AstraZeneca Clinical Study Information Center contact

1-877-240-9479

information.center@astrazeneca.com

143 sites in 15 countries: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing AZD0120, Daratumumab and Carfilzomib in people with Relapsed Refractory Multiple Myeloma, run by AstraZeneca at 143 sites in 15 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 16 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 29 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 143 sites in United States, China, Germany, Australia, Spain and 10 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact AstraZeneca Clinical Study Information Center (1-877-240-9479, information.center@astrazeneca.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

To demonstrate the superiority of AZD0120 relative to standard therapy (DKd, DPd, PVd, or Kd) by assessment of PFS in participants with RRMM. (time frame: 3 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07391657.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Sep 2026.